110 related articles for article (PubMed ID: 36943158)
21. The
Maffey-Steffan J; Scarpa L; Svirydenka A; Nilica B; Mair C; Buxbaum S; Bektic J; von Guggenberg E; Uprimny C; Horninger W; Virgolini I
Eur J Nucl Med Mol Imaging; 2020 Mar; 47(3):695-712. PubMed ID: 31776632
[TBL] [Abstract][Full Text] [Related]
22. FDA Approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic Castration-Resistant Prostate Cancer.
Fallah J; Agrawal S; Gittleman H; Fiero MH; Subramaniam S; John C; Chen W; Ricks TK; Niu G; Fotenos A; Wang M; Chiang K; Pierce WF; Suzman DL; Tang S; Pazdur R; Amiri-Kordestani L; Ibrahim A; Kluetz PG
Clin Cancer Res; 2023 May; 29(9):1651-1657. PubMed ID: 36469000
[TBL] [Abstract][Full Text] [Related]
23.
Pathmanandavel S; Crumbaker M; Yam AO; Nguyen A; Rofe C; Hovey E; Gedye C; Kwan EM; Hauser C; Azad AA; Eu P; Martin AJ; Joshua AM; Emmett L
J Nucl Med; 2022 Apr; 63(4):560-566. PubMed ID: 34326127
[No Abstract] [Full Text] [Related]
24. Prognostic importance of prostatic specific antigen response in patients who received Lutetium-177 prostate-specific membrane antigen treatment for castration resistant prostate cancer.
Soydal C; Araz M; Urun Y; Nak D; Ozkan E; Kucuk NO
Q J Nucl Med Mol Imaging; 2021 Sep; 65(3):282-286. PubMed ID: 31602963
[TBL] [Abstract][Full Text] [Related]
25. The role of Ga
Erdogan M; Sengul SS; Cetin B; Avcı M; Yagci S; Ozkoç I; Barikan DE; Yildiz M
Ann Nucl Med; 2022 Jun; 36(6):562-569. PubMed ID: 35397091
[TBL] [Abstract][Full Text] [Related]
26. A Retrospective Analysis of the Safety and Activity of Lutetium-177-Prostate-Specific Membrane Antigen Radionuclide Treatment in Older Patients with Metastatic Castration-Resistant Prostate Cancer.
Leibowitz R; Davidson T; Gadot M; Aharon M; Malki A; Levartovsky M; Oedegaard C; Saad A; Sandler I; Ben-Haim S; Domachevsky L; Berger R
Oncologist; 2020 Sep; 25(9):787-792. PubMed ID: 32430954
[TBL] [Abstract][Full Text] [Related]
27. Therapeutic Multidose Preparation of a Ready-to-Use
Chakraborty A; Mitra A; Tawate M; Sahoo S; Lad S; Rakshit S; Gaikwad S; Basu S; Shimpi H; Banerjee S
Cancer Biother Radiopharm; 2021 Oct; 36(8):682-692. PubMed ID: 34402687
[No Abstract] [Full Text] [Related]
28. Lutetium-177-PSMA-617: A Vision of the Future.
Chandran E; Figg WD; Madan R
Cancer Biol Ther; 2022 Dec; 23(1):186-190. PubMed ID: 35220877
[TBL] [Abstract][Full Text] [Related]
29. Predictors of Overall and Disease-Free Survival in Metastatic Castration-Resistant Prostate Cancer Patients Receiving
Sathekge M; Bruchertseifer F; Vorster M; Lawal IO; Knoesen O; Mahapane J; Davis C; Reyneke F; Maes A; Kratochwil C; Lengana T; Giesel FL; Van de Wiele C; Morgenstern A
J Nucl Med; 2020 Jan; 61(1):62-69. PubMed ID: 31101746
[TBL] [Abstract][Full Text] [Related]
30. First Experience With 177Lu-PSMA-617 Therapy for Advanced Prostate Cancer in the Netherlands.
van Kalmthout L; Braat A; Lam M; van Leeuwaarde R; Krijger G; Ververs T; Mehra N; Bins A; Hunting J; de Keizer B
Clin Nucl Med; 2019 Jun; 44(6):446-451. PubMed ID: 30985436
[TBL] [Abstract][Full Text] [Related]
31. 177 Lu-PSMA-617 radioligand therapy of metastatic castration-resistant prostate cancer: Initial 254-patient results from a prospective registry (REALITY Study).
Khreish F; Ghazal Z; Marlowe RJ; Rosar F; Sabet A; Maus S; Linxweiler J; Bartholomä M; Ezziddin S
Eur J Nucl Med Mol Imaging; 2022 Feb; 49(3):1075-1085. PubMed ID: 34494131
[TBL] [Abstract][Full Text] [Related]
32. Measuring response in metastatic castration-resistant prostate cancer using PSMA PET/CT: comparison of RECIST 1.1, aPCWG3, aPERCIST, PPP, and RECIP 1.0 criteria.
Gafita A; Rauscher I; Fendler WP; Murthy V; Hui W; Armstrong WR; Herrmann K; Weber WA; Calais J; Eiber M; Weber M; Benz MR
Eur J Nucl Med Mol Imaging; 2022 Oct; 49(12):4271-4281. PubMed ID: 35767071
[TBL] [Abstract][Full Text] [Related]
33. PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617.
Kratochwil C; Giesel FL; Stefanova M; Benešová M; Bronzel M; Afshar-Oromieh A; Mier W; Eder M; Kopka K; Haberkorn U
J Nucl Med; 2016 Aug; 57(8):1170-6. PubMed ID: 26985056
[TBL] [Abstract][Full Text] [Related]
34. Costs of radium-223 and the pharmacy preparation
Quist SW; Paulissen JHJ; Wyndaele DNJ; Nagarajah J; Freriks RD
J Med Econ; 2023; 26(1):366-375. PubMed ID: 36905581
[TBL] [Abstract][Full Text] [Related]
35. Should Lutetium-prostate specific membrane antigen radioligand therapy for metastatic prostate cancer be used earlier in men with lymph node only metastatic prostate cancer?
Yaxley WJ; McBean R; Wong D; Grimes D; Vasey P; Frydenberg M; Yaxley JW
Investig Clin Urol; 2021 Nov; 62(6):650-657. PubMed ID: 34729965
[TBL] [Abstract][Full Text] [Related]
36. Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of
Violet J; Sandhu S; Iravani A; Ferdinandus J; Thang SP; Kong G; Kumar AR; Akhurst T; Pattison DA; Beaulieu A; Mooi J; Tran B; Guo C; Kalff V; Murphy DG; Jackson P; Eu P; Scalzo M; Williams S; Hicks RJ; Hofman MS
J Nucl Med; 2020 Jun; 61(6):857-865. PubMed ID: 31732676
[No Abstract] [Full Text] [Related]
37. Hematologic toxicity profile and efficacy of [
Lawal IO; Morgenstern A; Vorster M; Knoesen O; Mahapane J; Hlongwa KN; Maserumule LC; Ndlovu H; Reed JD; Popoola GO; Mokoala KMG; Mdlophane A; Bruchertseifer F; Sathekge MM
Eur J Nucl Med Mol Imaging; 2022 Aug; 49(10):3581-3592. PubMed ID: 35384462
[TBL] [Abstract][Full Text] [Related]
38. [
Peters SMB; Hofferber R; Privé BM; de Bakker M; Gotthardt M; Janssen M; de Lange F; Muselaers CHJ; Mehra N; Witjes JA; Costa PF; Nagarajah J; Konijnenberg MW; Jentzen W
Eur J Nucl Med Mol Imaging; 2022 Mar; 49(4):1101-1112. PubMed ID: 34623453
[TBL] [Abstract][Full Text] [Related]
39. Total tumor volume reduction and low PSMA expression in patients receiving Lu-PSMA therapy.
Seifert R; Kessel K; Schlack K; Weckesser M; Kersting D; Seitzer KE; Weber M; Bögemann M; Rahbar K
Theranostics; 2021; 11(17):8143-8151. PubMed ID: 34373733
[No Abstract] [Full Text] [Related]
40. Nomograms to predict outcomes after
Gafita A; Calais J; Grogan TR; Hadaschik B; Wang H; Weber M; Sandhu S; Kratochwil C; Esfandiari R; Tauber R; Zeldin A; Rathke H; Armstrong WR; Robertson A; Thin P; D'Alessandria C; Rettig MB; Delpassand ES; Haberkorn U; Elashoff D; Herrmann K; Czernin J; Hofman MS; Fendler WP; Eiber M
Lancet Oncol; 2021 Aug; 22(8):1115-1125. PubMed ID: 34246328
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]